2-{ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-1-phenyl-ethanol | 872690-60-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-{ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-1-phenyl-ethanol
• 英文别名: 2-{Ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-1-phenyl-ethanol；2-[N-ethyl-4-(1,1,1,3,3,3-hexafluoro-2-triethylsilyloxypropan-2-yl)anilino]-1-phenylethanol
• CAS: 872690-60-3
• 化学式: C₂₅H₃₃F₆NO₂Si
• 分子量: 521.618
• InChiKey: IHLHDDNTYSBSEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  500.5±50.0 °C(Predicted)
• 密度：
  1.176±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.59
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-{ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-1-phenyl-ethanol 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以65%的产率得到2-{4-[ethyl-(2-hydroxy-2-phenyl-ethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol
  参考文献：
  名称：

  Novel hexafluoroisopropanol derivatives

  摘要：

  这项发明涉及式(I)的新型六氟异丙醇衍生物，其中R1至R6，m和n如描述和索赔中所定义，以及其生理上可接受的盐和酯。这些化合物结合到LXR alpha和LXR beta，并可用作药物。

  公开号：

  US20060004068A1
• 作为产物：
  描述：

  2-(4-氨基苯)-1,1,1,3,3,3-六氟-2-丙醇 在 吡啶 、 硼烷四氢呋喃络合物 、 Li₂ClO₄ 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-{ethyl-[4-(2,2,2-trifluoro-1-triethylsilanyloxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-1-phenyl-ethanol
  参考文献：
  名称：

  Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRα and β

  摘要：

  A series of branched and unbranched anilinohexafluoroisopropanols related to the known sulfonamide T0901317 were prepared and evaluated as activators/modulators of both LXR alpha and LXR beta. A structure-activity relationship was established and compounds with high potency on both the receptors were identified. Many compounds showed a tendency toward selectivity for LXR beta versus LXR alpha. Several analogues were evaluated for effects on plasma lipoprotein levels in mice. A few of these significantly raised HDL-cholesterol levels in plasma but showed markedly different effects on liver triglyceride content, suggesting that this series may yield candidates with improved efficacy/safety profiles compared to existing molecules. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.081

文献信息

• NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES
  申请人：Dehmlow Henrietta

  公开号：US20100004297A1

  公开（公告）日：2010-01-07

  The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I) wherein R 1 to R 6 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

  本发明涉及一种新型的六氟异丙醇衍生物，其化学式为（I），其中R1至R6，m和n的定义如说明书和权利要求中所述，以及其生理学上可接受的盐和酯。这些化合物与LXR alpha和LXR beta结合，并可用作药物。
• Hexafluoroisopropanol derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US07259178B2

  公开（公告）日：2007-08-21

  The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I) wherein R1 to R6, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

  本发明涉及公式（I）的新型六氟异丙醇衍生物，其中R1至R6、m和n如说明书和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物与LXR alpha和LXR beta结合，可用作药物。
• Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRα and β
  作者：Narendra Panday、Jörg Benz、Denise Blum-Kaelin、Vanessa Bourgeaux、Henrietta Dehmlow、Peter Hartman、Bernd Kuhn、Hassen Ratni、Xavier Warot、Matthew B. Wright

  DOI：10.1016/j.bmcl.2006.06.081

  日期：2006.10

  A series of branched and unbranched anilinohexafluoroisopropanols related to the known sulfonamide T0901317 were prepared and evaluated as activators/modulators of both LXR alpha and LXR beta. A structure-activity relationship was established and compounds with high potency on both the receptors were identified. Many compounds showed a tendency toward selectivity for LXR beta versus LXR alpha. Several analogues were evaluated for effects on plasma lipoprotein levels in mice. A few of these significantly raised HDL-cholesterol levels in plasma but showed markedly different effects on liver triglyceride content, suggesting that this series may yield candidates with improved efficacy/safety profiles compared to existing molecules. (c) 2006 Elsevier Ltd. All rights reserved.
• Novel hexafluoroisopropanol derivatives
  申请人：Dehmlow Henrietta

  公开号：US20060004068A1

  公开（公告）日：2006-01-05

  The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I) wherein R 1 to R 6 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

  这项发明涉及式(I)的新型六氟异丙醇衍生物，其中R1至R6，m和n如描述和索赔中所定义，以及其生理上可接受的盐和酯。这些化合物结合到LXR alpha和LXR beta，并可用作药物。